KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.LancetPMID 37290461PMC110177282023-Jul-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.J Clin Endocrinol MetabPMID 36734148PMC103484732023-Jul-140.98未发现恶性肿瘤人群证据。待处理
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).Clin Cancer ResPMID 37289007PMC105246892023-Jul-140.90The record describes a secondary biomarker analysis (plasma 25-hydroxyvitamin D) from a Phase III randomized trial (CALGB/SWOG 80702). While the underlying trial is eligible, this specific publication does not report on the original drug intervention's primary or key secondary efficacy results; it assesses an observational biomarker's association with survival, not the randomized drug comparison. Therefore, it is excluded as a non-primary drug result report.待处理
Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study).J Headache PainPMID 37452281PMC103477882023-Jul-140.98未发现恶性肿瘤人群证据。待处理
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.N Engl J MedPMID 37272527无 PMCID2023-Jul-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.J Clin OncolPMID 36795843无 PMCID2023-Jul-100.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).TrialsPMID 37430353PMC103320632023-Jul-100.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).Br J DermatolPMID 36999560无 PMCID2023-Jul-071.00The record describes a Phase III randomized trial of a drug (baricitinib) for atopic dermatitis, which is not an oncology indication. Although it is a randomized trial with a drug intervention and original results, it is excluded because it is non-oncology and lacks a primary/time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, or HR).待处理
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.N Engl J MedPMID 37345876无 PMCID2023-Jul-060.98未发现恶性肿瘤人群证据。待处理
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.OncologistPMID 37141403PMC103221232023-Jul-050.90The study is a randomized Phase III trial with a drug intervention in human oncology, but the primary efficacy endpoint (MMR rate at 24 weeks) is not a time-to-event outcome. No evidence of a time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio is provided in the abstract.待处理
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.J Am Coll CardiolPMID 37380301无 PMCID2023-Jul-040.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial.JAMA Netw OpenPMID 37490291PMC103702582023-Jul-030.98未发现恶性肿瘤人群证据。待处理
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer.Int J Radiat Oncol Biol PhysPMID 36549347PMC102475152023-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.Int J CancerPMID 36883420无 PMCID2023-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.AIDSPMID 36939067PMC102414182023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.J Clin OncolPMID 37071836无 PMCID2023-Jul-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.J Clin OncolPMID 37071838PMC103064352023-Jul-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide.Clin Transl GastroenterolPMID 37162147PMC103713182023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial.Clin Transl GastroenterolPMID 37235793PMC103713302023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.JAMA OphthalmolPMID 37289448PMC102512422023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study.PediatricsPMID 37309607无 PMCID2023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.LancetPMID 37331369无 PMCID2023-Jul-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.Allergy Asthma ProcPMID 37480206无 PMCID2023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact.Medicine (Baltimore)PMID 37499085PMC103741862023-Jul-010.98未发现恶性肿瘤人群证据。待处理
Resolution of outer retinal abnormalities in eyes with vitreomacular traction without macular hole in the OASIS trial.Br J OphthalmolPMID 35288439无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis.Arthritis Care Res (Hoboken)PMID 36039949无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.J Oncol Pharm PractPMID 36067063无 PMCID2023-Jul0.90The record describes a safety and patient preference analysis of a treatment switch within two Phase III trials. The primary endpoints are safety (adverse events) and patient-reported preference, not a formal primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) from a randomized trial.待处理
Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.MycosesPMID 36336989无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
A phase III, multi-arm multi-stage covariate-adjusted response-adaptive randomized trial to determine optimal early mobility training after stroke (AVERT DOSE).Int J StrokePMID 36398582无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Growth hormone treatment in pre-pubertal short Chinese children with chronic kidney disease prior to transplantation.Pediatr ResPMID 36539574无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies.Cancer Res TreatPMID 36701846PMC103725862023-Jul0.85The report is from a Phase III randomized trial in oncology with a drug intervention, but it does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). The primary endpoint is mean duration of severe neutropenia, which is a hematologic safety/efficacy surrogate, not a survival or progression endpoint. No Kaplan-Meier curves or hazard ratios for survival or progression are reported.待处理
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study.Diabetes Obes MetabPMID 36864540无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.OphthalmologyPMID 36870451无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.Eur UrolPMID 36870797无 PMCID2023-Jul0.60The record is an eligible-type report (Phase 3b, randomized, oncology, human, drug intervention, original result). However, the abstract is missing, and the title does not explicitly state a time-to-event efficacy endpoint (e.g., OS, PFS) or mention Kaplan-Meier/HR. Metadata cannot confirm the 'time_to_event' criterion without this information. Therefore, is_eligible is set to null.待处理
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.Diabetes Obes MetabPMID 36872067无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial.Lancet Infect DisPMID 36893784无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.Diabetes MetabPMID 36906135无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.Clin Microbiol InfectPMID 36921715PMC100100492023-Jul0.98未发现恶性肿瘤人群证据。待处理
A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.J Am Acad DermatolPMID 36990320无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.Diabetes Obes MetabPMID 36999231无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.ProstatePMID 37071764无 PMCID2023-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.Clin Lung CancerPMID 37076395无 PMCID2023-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101.Transplant Cell TherPMID 37088401PMC103301362023-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.Neurol Neuroimmunol NeuroinflammPMID 37094998PMC101366822023-Jul0.98未发现恶性肿瘤人群证据。待处理
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.Gastric CancerPMID 37106214PMC102847302023-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.J UrolPMID 37119051无 PMCID2023-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101.Transplant Cell TherPMID 37120135PMC103533082023-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.Eur UrolPMID 37121850无 PMCID2023-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006-2020.Clin Pharmacol TherPMID 37129347无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.J DermatolPMID 37154471无 PMCID2023-Jul0.98未发现恶性肿瘤人群证据。待处理